189 related articles for article (PubMed ID: 35169093)
1. [The Potential of Personalized/Precision Medicine for Meningiomas].
Yamaguchi S; Fujimura M
No Shinkei Geka; 2022 Jan; 50(1):132-140. PubMed ID: 35169093
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
3. Medical management of meningioma in the era of precision medicine.
Gupta S; Bi WL; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E3. PubMed ID: 29606052
[TBL] [Abstract][Full Text] [Related]
4. Genomic landscape of intracranial meningiomas.
Bi WL; Abedalthagafi M; Horowitz P; Agarwalla PK; Mei Y; Aizer AA; Brewster R; Dunn GP; Al-Mefty O; Alexander BM; Santagata S; Beroukhim R; Dunn IF
J Neurosurg; 2016 Sep; 125(3):525-35. PubMed ID: 26771848
[TBL] [Abstract][Full Text] [Related]
5. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
6. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.
Peyre M; Kalamarides M
Neurochirurgie; 2018 Mar; 64(1):22-28. PubMed ID: 25245924
[TBL] [Abstract][Full Text] [Related]
8. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
9. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
11. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
12. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
Cordova C; Kurz SC
Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
[TBL] [Abstract][Full Text] [Related]
13. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of meningiomas: from basic research to potential clinical applications.
Simon M; Boström JP; Hartmann C
Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514
[TBL] [Abstract][Full Text] [Related]
15. Meningioma genomics: a therapeutic challenge for clinicians.
Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
[TBL] [Abstract][Full Text] [Related]
16. The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
Robert SM; Vetsa S; Nadar A; Vasandani S; Youngblood MW; Gorelick E; Jin L; Marianayagam N; Erson-Omay EZ; Günel M; Moliterno J
J Neurooncol; 2022 Jan; 156(2):205-214. PubMed ID: 34846640
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of meningiomas.
Youngblood MW; Günel M
Handb Clin Neurol; 2020; 169():101-119. PubMed ID: 32553282
[TBL] [Abstract][Full Text] [Related]
18. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
19. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
20. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
